Cell Signaling Technology

Dynamin 1/2 Antibody

#2342 · $317

100
Citing papers
18.6k
Combined citations
Supplier page Find this product

Research areas

Cancer, Hypoxia, and Metabolism8Autophagy in Disease and Therapy7NF-κB Signaling Pathways6Ubiquitin and proteasome pathways5MicroRNA in disease regulation5Melanoma and MAPK Pathways5Neuroscience and Neuropharmacology Research5Fibroblast Growth Factor Research4

Papers citing this product

1
Candidalysin is a fungal peptide toxin critical for mucosal infection
Nature·2016·891 cit.·DOI
2
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Cell·2020·811 cit.·DOI
3
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Journal of Neuroscience·2003·663 cit.·DOI
4
Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
Journal of Clinical Oncology·2006·523 cit.·DOI
5
Cartilage Tissue Engineering by the 3D Bioprinting of iPS Cells in a Nanocellulose/Alginate Bioink
Scientific Reports·2017·475 cit.·DOI
6
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Nature Communications·2017·440 cit.·DOI
7
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming
Nature Communications·2021·414 cit.·DOI
8
Delta-like 4 is indispensable in thymic environment specific for T cell development
The Journal of Experimental Medicine·2008·380 cit.·DOI
9
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
British Journal of Cancer·2010·313 cit.·DOI
10
Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis
Nature Communications·2019·301 cit.·DOI

Similar products

ProductVendorEvidencePricePapers
Dynamin (pan) (F2E9N) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology—$161,3761

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.